Grey Fox Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Grey Fox Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$71	–	428
2025 Q3	$71	Buy	+6	New	+$56	﹤0.01%	644
2023 Q2	–	Sell	-6	Closed	-$19	–	364
2023 Q1	$19	Buy	+6	New	+$20	﹤0.01%	526

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Grey Fox Wealth Advisors's DFTX Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 6 shares — an estimated $71 sold.

Grey Fox Wealth Advisors first reported a position in DFTX in Q1 2023 and held it in 2 quarters. The position peaked at $71 in Q3 2025. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

Grey Fox Wealth Advisors reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
Grey Fox Wealth Advisors sold 6 Definium Therapeutics shares in Q4 2025, an estimated $71.
Grey Fox Wealth Advisors first reported a position in Definium Therapeutics in Q1 2023 and held it in 2 quarters.
Grey Fox Wealth Advisors's Definium Therapeutics position peaked at $71 in Q3 2025.
208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.